DEFM14A: Vigil Neuroscience to be Acquired by Sanofi for $10.00 Per Share, Including Contingent Value Right

Vigil Neuroscience, a clinical-stage biotechnology company, has entered into a definitive merger agreement to be acquired by Sanofi for $8.00 per share in upfront cash plus a contingent value right of $2.00 per share, contingent on the achievement of a key clinical milestone for VG-3927.

Summary

• Vigil Neuroscience, Inc. (the Company) will be acquired by Sanofi through a merger with Sanofi's wholly-owned subsidiary, Vesper Acquisition Sub Inc. (Merger Sub).
• Each outstanding share of Company common stock will be converted into the right to receive $8.00 in cash, without interest, plus one contractual contingent value right (CVR) representing the right to receive an additional $2.00 in cash upon the First Commercial Sale of VG-3927 between the Effective Time and December 31, 2035.
• The Board of Directors unanimously determined the merger to be advisable and fair to, and in the best interest of, the Company and its stockholders, recommending a 'FOR' vote on the Transaction Proposal and Adjournment Proposal.
• The merger consideration represents a premium of approximately 333% over the closing price of Company common stock ($2.31) on May 21, 2025, and a 350% premium over the 30-day volume-weighted average price ($2.22) as of the same date.
• Supporting Stockholders, including the CEO and Atlas Venture entities, collectively beneficially owned approximately 16.54% of the total voting power and have agreed to vote in favor of the merger.
• All unvested Company Options and Company RSUs will accelerate and become fully vested immediately prior to, and contingent upon, the Effective Time.
• Company Options with an exercise price less than $8.00 will be cashed out based on the difference between $8.00 and the exercise price, plus one CVR per share. Options with an exercise price between $8.00 and $10.00 will receive one CVR per share, with a potential cash payment of $10.00 minus the exercise price if the milestone is achieved. Options with an exercise price of $10.00 or greater will be canceled for no consideration.
• Company RSUs will be cashed out at $8.00 per share plus one CVR per share.
• The merger is anticipated to be completed in the third quarter of 2025, subject to stockholder approval and regulatory clearances.
• The Company and Parent filed notification of the proposed merger with the FTC and DOJ under the HSR Act on June 16, 2025, with the waiting period expiring on July 16, 2025.
• The rights to Vigil's first clinical candidate, iluzanebart (VGL101), a fully human monoclonal antibody TREM2 agonist, are being returned to Amgen, the original licensor, prior to the closing of the transaction with Sanofi.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the significant premium offered to shareholders, providing immediate liquidity and a substantial return compared to recent trading prices. The CVR offers additional upside potential, and the acquisition by a major pharmaceutical company like Sanofi de-risks future development and commercialization for Vigil's key asset. The Board's unanimous recommendation and the support from major shareholders further reinforce the positive outlook for the transaction.

Positives

• The merger consideration offers a significant premium of 333% over the closing price and 350% over the 30-day volume-weighted average price of Company common stock as of May 21, 2025, providing immediate and certain liquidity to stockholders.
• The inclusion of a Contingent Value Right (CVR) provides an opportunity for stockholders to realize additional value of up to $2.00 per share if the First Commercial Sale of VG-3927 occurs by December 31, 2035.
• Sanofi's extensive resources, capabilities, and experience in biopharmaceutical product development and commercialization enhance the likelihood of achieving the CVR milestone for VG-3927 compared to Vigil's standalone capabilities.
• The transaction provides certainty of value in a challenging financing environment for biotechnology companies, mitigating risks associated with the need for additional capital and potential significant dilution if Vigil remained a standalone entity.
• The Board of Directors unanimously approved the merger, indicating strong internal support for the transaction.
• Key stockholders, including the CEO and Atlas Venture, representing approximately 16.54% of voting power, have entered into voting and support agreements in favor of the merger, increasing the likelihood of stockholder approval.
• The merger agreement includes a reverse termination fee of $31,144,620 payable by Parent under certain antitrust-related termination circumstances, providing some protection to Vigil.

Negatives

• The CVR payment of $2.00 is contingent on the First Commercial Sale of VG-3927 by December 31, 2035, and there is no assurance that this milestone will be achieved, meaning the full $10.00 per share consideration is not guaranteed.
• The transaction price, while offering a premium, means Company stockholders will not participate in any potential future growth or appreciation in the value or earnings of Vigil Neuroscience beyond the CVR payment.
• The complexity and duration of negotiations regarding the return of VGL101 to Amgen negatively impacted the value Sanofi was willing to pay for Vigil, leading to a reduction in the CVR value from an initial proposal of up to $4.00 to $2.00 per share.
• The merger agreement includes a termination fee of $22,246,157 payable by Vigil under certain circumstances, including if Vigil accepts a superior offer, which could deter competing bids.
• The pendency of the merger and certain pre-closing covenants may disrupt Vigil's business operations and potentially impact relationships with employees and partners.
• Executive officers and directors have interests in the merger (e.g., accelerated equity vesting, severance, potential tax gross-ups) that may differ from general stockholder interests.

Risks

• The CVR payment is contingent on the First Commercial Sale of VG-3927 by December 31, 2035, and there is no assurance that this milestone will be achieved, meaning the $2.00 CVR payment may not be received.
• The closing of the merger is subject to various conditions, including regulatory approvals and stockholder approval, and there is a risk that these conditions may not be satisfied or may be delayed.
• If the Amgen Closing Condition (related to the return of VGL101 rights) is not satisfied or waived by Parent by September 15, 2025, Parent has the right to terminate the Merger Agreement.
• The Company faces significant risks and uncertainties associated with continued development and regulatory approval efforts for its product candidates, including the inherent uncertainty of clinical trial outcomes and the challenges of obtaining regulatory approvals.
• The biopharmaceutical and biotechnology industry is subject to complex regulatory and political regimes, evolving pricing environments, and intense competition, which could impact future revenue and profitability.
• There is a risk of litigation and/or regulatory actions related to the proposed merger, which could result in significant costs or delays.
• The merger consideration may be a taxable event for U.S. holders, and the tax treatment of CVRs is uncertain, potentially leading to complex tax consequences.
• Potential difficulties in employee retention may arise as a result of the announcement and pendency of the merger.

Future Outlook

The merger will result in Vigil Neuroscience becoming a wholly-owned subsidiary of Sanofi, leading to its delisting from Nasdaq and deregistration under the Exchange Act. The future success of the contingent value right (CVR) payment depends on Sanofi's diligent efforts to achieve the First Commercial Sale of VG-3927 by December 31, 2035. The Company's management had prepared long-range financial projections through 2043 as a standalone entity, but these will not be realized post-merger. The transaction is expected to close in the third quarter of 2025.

Management Comments

• The Board of Directors unanimously determined that the Merger Agreement and the Transactions, including the Merger, are advisable and fair to, and in the best interest of, the Company and its stockholders.
• The Board of Directors unanimously recommends that the Company stockholders vote FOR the Transaction Proposal and FOR the Adjournment Proposal.
• Dr. Ivana Magovevi-Liebisch, President and Chief Executive Officer, signed the letter to stockholders and the merger agreement on behalf of Vigil Neuroscience, Inc.

Industry Context

This acquisition highlights the ongoing consolidation and strategic partnerships within the biopharmaceutical industry, particularly in the neurodegenerative disease space. Sanofi, a global healthcare company, is expanding its pipeline by acquiring Vigil's TREM2 agonist programs, especially VG-3927 for Alzheimer's disease. The return of VGL101 to Amgen indicates a strategic focus shift for Vigil's assets prior to the acquisition, allowing Sanofi to focus on the small molecule TREM2 platform. The challenging financing environment for standalone biopharmaceutical companies, as noted by Vigil's board, likely played a role in the decision to pursue an acquisition rather than continued independent operation and fundraising.

Comparison to Industry Standards

• Centerview Partners LLC's analysis of precedent premiums paid in selected transactions involving publicly traded biopharmaceutical companies indicated an implied price range of approximately $4.45 to $7.45 per share, based on applying an 80% to 200% premium to Vigil's closing stock price of $2.48 on May 20, 2025. The total potential merger consideration of $10.00 per share (including CVR) exceeds this range, suggesting a favorable outcome for Vigil's stockholders compared to recent industry precedents.
• The upfront cash consideration of $8.00 per share alone represents a 246% premium to Vigil's closing price on May 21, 2025, which is significantly higher than typical premiums observed in biopharmaceutical acquisitions, indicating a strong valuation for Vigil's assets, particularly its small molecule TREM2 agonist platform.
• The structure of the deal, including a CVR, is common in biotech acquisitions, allowing the acquirer to mitigate risk associated with clinical development while providing upside potential to the acquired company's shareholders upon milestone achievement. The $2.00 CVR for VG-3927's first commercial sale by 2035 reflects the long-term nature and inherent risks of neurodegenerative drug development.

Management Changes

Corporate Governance

Legal Proceedings

• As of the date of the proxy statement, there are no legal proceedings pending challenging the Merger.

Related Party Transactions

• Sanofi, the Parent company, holds all issued and outstanding Company Series A Non-Voting Convertible Preferred Stock as of May 21, 2025.
• Ivana Magovevi-Liebisch (CEO), Bruce Booth, Atlas Venture Fund XII, L.P., and Atlas Venture Opportunity Fund I, L.P. (collectively, the Supporting Stockholders) entered into voting and support agreements with Parent. These Supporting Stockholders collectively beneficially owned approximately 16.54% of the total voting power of outstanding Company common stock as of the record date and agreed to vote in favor of the merger.

Stakeholder Impact

• **Shareholders**: Will receive $8.00 in cash per share upfront and a contingent right to an additional $2.00 per share, representing a significant premium over recent trading prices. Those who do not vote in favor and follow specific procedures may exercise appraisal rights to seek fair value as determined by the Delaware Court of Chancery.
• **Employees**: Current employees who continue employment with the Surviving Corporation will receive a base salary and target annual cash incentive compensation no less favorable than prior to the merger for one year. Broad-based employee benefits will be substantially comparable in aggregate for one year. Unvested equity awards (options and RSUs) will accelerate and become fully vested upon the Effective Time.
• **Management/Directors**: Executive officers and directors holding equity awards will benefit from accelerated vesting and cash-out provisions. Executive officers are also eligible for severance payments and benefits under pre-existing employment agreements in case of a change in control termination, and potential tax gross-up payments for excise taxes under Section 4999 of the Code.
• **Creditors**: The document does not explicitly detail impact on creditors, but the acquisition by a larger, financially robust entity like Sanofi generally implies a stronger financial backing for existing liabilities.
• **Customers/Suppliers**: The document does not explicitly detail impact on customers or suppliers, but the merger is expected to integrate Vigil's operations into Sanofi's, potentially leading to changes in existing relationships or operational procedures.

Next Steps

• Hold a Special Meeting of Stockholders on August 4, 2025, to vote on the Transaction Proposal and Adjournment Proposal.
• Complete the merger in the third quarter of 2025, assuming timely receipt of required regulatory approvals and satisfaction of other closing conditions.
• Sanofi will enter into a Contingent Value Rights Agreement with a rights agent at or prior to the Effective Time.
• Upon completion of the merger, Vigil Neuroscience common stock will be delisted from Nasdaq and deregistered under the Exchange Act.
• Parent is obligated to use Diligent Efforts to achieve the First Commercial Sale of VG-3927 by December 31, 2035, for the CVR payment.

Key Dates

Recommendation

Keywords

Merger, Acquisition, Biotechnology, Neurodegenerative Diseases, TREM2 Agonist, VG-3927, Contingent Value Right, CVR, Sanofi, Vigil Neuroscience, SEC Filing, Proxy Statement, Clinical Stage, Drug Development, Shareholder Vote, M&A